AGPS and psoriasis: The prevalence of ADAs was 5.3%75 and 9%76 in adult patients with psoriasis and PsA, respectively, and they occurredwithin the first 12 weeks of treatment.76 ADAs were found to be non-neutralising and did not correlate with therate of adverse reactions (Table 2).